

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Kindstar Globalgene Technology, Inc.**  
**康聖環球基因技術有限公司**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 9960)**

**SHARE PURCHASE PURSUANT TO THE  
POST-IPO RSU SCHEME**

Reference is made to the Post-IPO RSU Scheme of the Company approved and adopted by the Board on June 22, 2021, and the announcements of the Company dated March 25, 2022 and March 31, 2022 in relation to the intended share purchase pursuant to the Post-IPO RSU Scheme (the “**Announcements**”). Unless otherwise stated, capitalized terms used in this announcement shall have the same meanings as defined in the Announcements.

From April 1, 2022 to May 31, 2022, the RSU Trustee had utilized an aggregate of HK\$12,452,525 to purchase 4,945,000 Shares from the market at a consideration of HK\$2.12 to HK\$2.78 per Share to hold on trust for the benefit of the selected participants pursuant to the rules of the Post-IPO RSU Scheme. The Shares so purchased will be used as Awards for the selected participants in the Post-IPO RSU Scheme to encourage them to make contributions to the long-term growth and profits of the Company. In addition, the share purchase pursuant to the Post-IPO RSU Scheme also demonstrates the Company’s confidence in its business outlook and prospect. The Company will continue to implement the share purchase plan pursuant to the Post-IPO RSU Scheme on market based on market conditions.

By order of the Board  
**Kindstar Globalgene Technology, Inc.**  
康聖環球基因技術有限公司  
**HUANG Shiang**  
Chairman

Hong Kong, June 6, 2022

*As of the date of this announcement, the Board comprises Dr. Huang Shiang, Mr. Tu Zanbing and Ms. Chai Haijie as executive Directors, Mr. Huang Zuie-Chin, Mr. Peng Wei and Ms. Huang Lu as non-executive Directors, and Dr. Yao Shanglong, Dr. Xia Xinping and Mr. Gu Huaming as independent non-executive Directors.*